» Download Public Reports
About 500 reports
- Company report
- February 2013
- 14 pages
- by Corporation
... Nervous system (cns) such as respiratory and nerve centre depression. Sales of this drug have already started in 1q13, but sihuan expects sales to become more meaningful only in next year. Sihuan expects ...
February 2013
... By analysis of data, we can understand medicine industry do not pay attention to intellectual property rights in qinghai province. In recent years, the patent application has been commonly used to measure ...
February 2013
... Recalls knee replacement Study shows lyrica as effective as antiseizure Durata sees positive results from dalbavancin Dynavax's hepatitis b vaccine needs further New products, announcements ...
March 2013
... With oxaliplatin injection and its active pharmaceutical ingredients (antineoplastic drug), gemcitabine hydrochloride injection and its active pharmaceutical ingredients (antineoplastic drug) and fasudil ...
March 2013
... In revenues last year, and earned $177.5 Million in net income. Its cro division generated 74% of its revenues. Also noted: quintiles helped develop or commercialize 85% of the central nervous system drugs ...
March 2013
... Agreement, the company and its subsidiaries will cease to engage in the distribution, sales and promotion of vaccines and cold-chain pharmaceutical products, directly or indirectly, as these businesses ...
April 2013
... Including roche, a cancer drug with sales recently forecasted to $7 billion out to 2015; and tecfidera, the new multiple sclerosis drug that made it to market in less than a 3 week of being approved ...
March 2013
... Step, if not to target (generally hba1c) consider first line consider second line consider third line consider fourth line or Or basal or premix qd/bid insulin secretagogue, gi ...
March 2013
... For aids vaccine Started clinical trial ii for aids vaccine Started manufacture rabies vaccine Varicella vaccine, live on market Approval for clinical trial of a peptide drug Established ...
» Purchase Premium Reports
(From $ 125 - $ 4 995)
About 300 reports
- $ 4 995
- Industry report
- February 2013
- by Global Data
PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis ...
May 2013
$ 5 174
This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 10 global countries. The studies provide essential market information ...
April 2013
$ 3 500
Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants ...
April 2013
$ 2 100
In recent years, China's Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Ove ...
May 2013
$ 2 000
China's demand for osteoporosis treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic ...
May 2013
$ 2 000
China's demand for anti-obesity drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, ...
May 2013
$ 2 000
China's demand for mental illness treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's ...
